Pediatric Moyamoya Disease and Syndrome in Italy: A Multicenter Cohort.
arteriopathy
aspirin
cerebrovascular events
headache
indirect revascularization
moyamoya
stroke
transient ischemic attack
Journal
Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
03
2022
accepted:
05
04
2022
entrez:
23
5
2022
pubmed:
24
5
2022
medline:
24
5
2022
Statut:
epublish
Résumé
Moyamoya is a rare progressive cerebral arteriopathy, occurring as an isolated phenomenon (moyamoya disease, MMD) or associated with other conditions (moyamoya syndrome, MMS), responsible for 6-10% of all childhood strokes and transient ischemic attacks (TIAs). We conducted a retrospective multicenter study on pediatric-onset MMD/MMS in Italy in order to characterize disease presentation, course, management, neuroradiology, and outcome in a European country. A total of 65 patients (34/65 women) with MMD (27/65) or MMS (38/65) were included. About 18% (12/65) of patients were asymptomatic and diagnosed incidentally during investigations performed for an underlying condition (incMMS), whereas 82% (53/65) of patients with MMD or MMS were diagnosed due to the presence of neurological symptoms (symptMMD/MMS). Of these latter, before diagnosis, 66% (43/65) of patients suffered from cerebrovascular events with or without other manifestations (ischemic stroke 42%, 27/65; TIA 32%, 21/65; and no hemorrhagic strokes), 18% (12/65) of them reported headache (in 4/12 headache was not associated with any other manifestation), and 26% (17/65) of them experienced multiple phenotypes (≥2 among: stroke/TIA/seizures/headache/others). Neuroradiology disclosed ≥1 ischemic lesion in 67% (39/58) of patients and posterior circulation involvement in 51% (30/58) of them. About 73% (47/64) of patients underwent surgery, and 69% (45/65) of them received aspirin, but after diagnosis, further stroke events occurred in 20% (12/61) of them, including operated patients (11%, 5/47). Between symptom onset and last follow-up, the overall patient/year incidence of stroke was 10.26% (IC 95% 7.58-13.88%). At last follow-up (median 4 years after diagnosis, range 0.5-15), 43% (26/61) of patients had motor deficits, 31% (19/61) of them had intellectual disability, 13% (8/61) of them had epilepsy, 11% (7/61) of them had behavioral problems, and 25% (13/52) of them had mRS > 2. The proportion of final mRS > 2 was significantly higher in patients with symptMMD/MMS than in patients with incMMS ( Moyamoya is a severe condition that may affect young children and frequently cause cerebrovascular events throughout the disease course, but may also manifest with multiple and non-cerebrovascular clinical phenotypes including headache (isolated or associated with other manifestations), seizures, and movement disorder. Younger onset age and stroke before diagnosis may associate with increased risk of worse outcome (final mRS > 2).
Sections du résumé
Background
UNASSIGNED
Moyamoya is a rare progressive cerebral arteriopathy, occurring as an isolated phenomenon (moyamoya disease, MMD) or associated with other conditions (moyamoya syndrome, MMS), responsible for 6-10% of all childhood strokes and transient ischemic attacks (TIAs).
Methods
UNASSIGNED
We conducted a retrospective multicenter study on pediatric-onset MMD/MMS in Italy in order to characterize disease presentation, course, management, neuroradiology, and outcome in a European country.
Results
UNASSIGNED
A total of 65 patients (34/65 women) with MMD (27/65) or MMS (38/65) were included. About 18% (12/65) of patients were asymptomatic and diagnosed incidentally during investigations performed for an underlying condition (incMMS), whereas 82% (53/65) of patients with MMD or MMS were diagnosed due to the presence of neurological symptoms (symptMMD/MMS). Of these latter, before diagnosis, 66% (43/65) of patients suffered from cerebrovascular events with or without other manifestations (ischemic stroke 42%, 27/65; TIA 32%, 21/65; and no hemorrhagic strokes), 18% (12/65) of them reported headache (in 4/12 headache was not associated with any other manifestation), and 26% (17/65) of them experienced multiple phenotypes (≥2 among: stroke/TIA/seizures/headache/others). Neuroradiology disclosed ≥1 ischemic lesion in 67% (39/58) of patients and posterior circulation involvement in 51% (30/58) of them. About 73% (47/64) of patients underwent surgery, and 69% (45/65) of them received aspirin, but after diagnosis, further stroke events occurred in 20% (12/61) of them, including operated patients (11%, 5/47). Between symptom onset and last follow-up, the overall patient/year incidence of stroke was 10.26% (IC 95% 7.58-13.88%). At last follow-up (median 4 years after diagnosis, range 0.5-15), 43% (26/61) of patients had motor deficits, 31% (19/61) of them had intellectual disability, 13% (8/61) of them had epilepsy, 11% (7/61) of them had behavioral problems, and 25% (13/52) of them had mRS > 2. The proportion of final mRS > 2 was significantly higher in patients with symptMMD/MMS than in patients with incMMS (
Conclusions
UNASSIGNED
Moyamoya is a severe condition that may affect young children and frequently cause cerebrovascular events throughout the disease course, but may also manifest with multiple and non-cerebrovascular clinical phenotypes including headache (isolated or associated with other manifestations), seizures, and movement disorder. Younger onset age and stroke before diagnosis may associate with increased risk of worse outcome (final mRS > 2).
Identifiants
pubmed: 35601411
doi: 10.3389/fped.2022.892445
pmc: PMC9120837
doi:
Types de publication
Journal Article
Langues
eng
Pagination
892445Informations de copyright
Copyright © 2022 Po', Nosadini, Zedde, Pascarella, Mirone, Cicala, Rosati, Cosi, Toldo, Colombatti, Martelli, Iodice, Accorsi, Giordano, Savasta, Foiadelli, Sanfilippo, Lafe, Thyrion, Polonara, Campa, Raviglione, Scelsa, Bova, Greco, Cordelli, Cirillo, Toni, Baro, Causin, Frigo, Suppiej, Sainati, Azzolina, Agostini, Cesaroni, De Carlo, Di Rosa, Esposito, Grazian, Morini, Nicita, Operto, Pruna, Ragazzi, Rollo, Spalice, Striano, Skabar, Lanterna, Carai, Marras, Manara and Sartori.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Neurol Med Chir (Tokyo). 2012;52(5):245-66
pubmed: 22870528
Neurology. 2020 Jun 9;94(23):e2479-e2490
pubmed: 32457211
Pediatr Neurol. 2017 Apr;69:58-70
pubmed: 28254555
Neurosurg Focus. 2011 Dec;31(6):E6
pubmed: 22133171
Circulation. 2009 Mar 17;119(10):1417-23
pubmed: 19255344
Bone Marrow Transplant. 2018 May;53(5):644-646
pubmed: 29335630
Headache. 2014 May;54(5):899-908
pubmed: 24766291
Acta Neurochir Suppl. 2016;123:129-32
pubmed: 27637639
Appl Clin Genet. 2021 Mar 18;14:145-171
pubmed: 33776470
Stroke. 2008 Sep;39(9):2644-91
pubmed: 18635845
Stroke. 2014 Mar;45(3):887-8
pubmed: 24523040
Stroke. 2019 Mar;50(3):e51-e96
pubmed: 30686119
J Stroke Cerebrovasc Dis. 2015 Jun;24(6):1204-10
pubmed: 25866319
Neuropediatrics. 2005 Apr;36(2):90-7
pubmed: 15822021
J Clin Neurosci. 2005 Nov;12(8):873-7
pubmed: 16257213
Eur J Neurol. 2012 Jan;19(1):163-7
pubmed: 21771204
Orphanet J Rare Dis. 2013 Oct 20;8:169
pubmed: 24139596
Am J Med Genet A. 2017 Jun;173(6):1521-1530
pubmed: 28422438
Acta Neurochir (Wien). 2003 Dec;145(12):1061-71; discussion 1071
pubmed: 14663563
J Neurosurg Pediatr. 2018 Aug;22(2):173-180
pubmed: 29856299
J Neurosurg Pediatr. 2013 Dec;12(6):626-32
pubmed: 24138143
Pediatr Neurol. 1998 Apr;18(4):321-5
pubmed: 9588527
Stroke. 2018 Dec 7;:STROKEAHA118023060
pubmed: 30580701
Neurosurgery. 2004 Apr;54(4):840-4; discussion 844-6
pubmed: 15046649
Neurosurg Focus. 2011 Jun;30(6):E21
pubmed: 21631223
N Engl J Med. 2009 Mar 19;360(12):1226-37
pubmed: 19297575
Childs Nerv Syst. 2014 May;30(5):885-90
pubmed: 24337519
Ann Neurol. 2020 Jun;87(6):840-852
pubmed: 32215969
Front Neurol. 2019 Jan 22;10:14
pubmed: 30723451
Stroke. 2008 Dec;39(12):3193-200
pubmed: 18787200
Dev Med Child Neurol. 2012 Jan;54(1):30-7
pubmed: 22117564
J Neurosurg Pediatr. 2012 Apr;9(4):353-60
pubmed: 22462697
Indian J Pediatr. 2013 Dec;80(12):1015-20
pubmed: 23525975
Childs Nerv Syst. 2021 Jun;37(6):2011-2023
pubmed: 33694129
Stroke. 1988 Dec;19(12):1497-500
pubmed: 3201508
Pediatr Neurol. 2017 Oct;75:48-54
pubmed: 28778481
Clin Neurol Neurosurg. 1997 Oct;99 Suppl 2:S54-7
pubmed: 9409406
J Neurol. 2019 Mar;266(3):574-581
pubmed: 30560456
Neurosurgery. 2017 Jun 1;80(6):950-956
pubmed: 28327981
Eur J Neurol. 2015 Jun;22(6):1012-7
pubmed: 25847099
Neurology. 2018 Feb 27;90(9):e763-e770
pubmed: 29483323
Ann Neurol. 2010 Jul;68(1):92-101
pubmed: 20582955
Ir J Med Sci. 2021 Feb;190(1):335-344
pubmed: 32562218
J Med Genet. 2017 Aug;54(8):550-557
pubmed: 28343148
World Neurosurg. 2019 Jul;127:e843-e855
pubmed: 30954732
Appl Clin Genet. 2015 Feb 16;8:49-68
pubmed: 25733922
J Neurosurg. 2009 Nov;111(5):927-35
pubmed: 19463046
Chest. 2012 Feb;141(2 Suppl):e737S-e801S
pubmed: 22315277
J Neurosurg. 2004 Feb;100(2 Suppl Pediatrics):142-9
pubmed: 14758941
Eur J Neurol. 2020 Dec;27(12):2446-2452
pubmed: 32668488
J Neurosurg. 2005 Nov;103(5 Suppl):439-42
pubmed: 16302616
Cerebrovasc Dis. 2012;33(1):76-9
pubmed: 22134052
Thromb Haemost. 2015 Jun;113(6):1270-7
pubmed: 25761414
Neurol Med Chir (Tokyo). 2015;55(3):189-93
pubmed: 25739428
Cerebrovasc Dis. 2011;32(4):361-9
pubmed: 21921600
Neurol Sci. 2019 Mar;40(3):561-570
pubmed: 30604336
J Stroke. 2016 Jan;18(1):21-30
pubmed: 26846757